{"input_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1845936/full","gnews_decode":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1845936/full","http_status":200,"final_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1845936/full","html_length":1730258,"trafilatura_result":"ok","text_length":128225,"text_preview":"Abstract\nThe gastrin-releasing peptide receptor (GRPR) is aberrantly expressed in several malignancies, including prostate cancer, breast cancer, lung cancer, and gastrointestinal stromal tumors, making it an important target for molecular imaging and targeted radionuclide therapy. In recent years, ","verdict":"OK"}